SCHEMBL7128067

SCHEMBL7128067

Cc1ncc(-c2cccc(Nc3nnc4c5c(cccc35)-c3ccccc3-4)c2)n1C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
KDR P35968 3/20 0.40
MAPT P10636 7/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
HPGD P15428 2/20 0.40
KDM4E B2RXH2 1/20 0.40
PDE5A O76074 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
ALOX15 P16050 1/20 0.40
CYP2C19 P33261 1/20 0.40
PDE1A P54750 1/20 0.40
PDE1B Q01064 1/20 0.40
PDE3B Q13370 1/20 0.40
PDE1C Q14123 1/20 0.40
PDE3A Q14432 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7127463 0.82 IDO1 (0.43) ALDH1A1NPC1RAB9AKDRMAPT
SCHEMBL7127650 0.81 MAPT (0.46) ALDH1A1NPC1RAB9AKDRMAPT
SCHEMBL7127543 0.77 KDR (0.54) ALDH1A1NPC1RAB9AKDRKMT2A
SCHEMBL7127458 0.77 ALDH1A1 (0.42) ALDH1A1NPC1RAB9AKDRMAPT
SCHEMBL7128105 0.76 BTK (0.39) ALDH1A1NPC1RAB9AMAPTSMN1; SMN2
SCHEMBL7128079 0.74 KDR (0.52) KDRKMT2AGSK3BDYRK1A
SCHEMBL7117372 0.74 AHR (0.47) ALDH1A1KDRMAPTSMN1; SMN2HPGD
SCHEMBL7125034 0.73 RIPK2 (0.42) ALDH1A1MAPTHPGDKDM4ECYP1A2
SCHEMBL7124246 0.72 RIPK2 (0.43) ALDH1A1NPC1RAB9AMAPTKDM4E
SCHEMBL7120296 0.71 RIPK2 (0.41) ALDH1A1NPC1RAB9AKDRMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030176454-A1 N-coating heterocyclic compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-09-18 US disclosed
WO-2001087845-A2 N-CONTAINING HETEROCYCLIC COMPOUNDS AND THEIR USE AS 5-HT ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-11-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176454-A1 N-coating heterocyclic compounds H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, GNE, NIT2 ALDH1A1 2482/4885NPC1 310/4885RAB9A 1556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.